Introduction {#Sec1}
============

Not infrequently, patients undergoing dual antiplatelet therapy for a recent cardiac stent subsequently require non-cardiac surgery. These surgeries can mostly be delayed while the antiplatelet treatment is stopped and normal platelet function returns in order to avoid potential surgical complications and excessive bleeding. However, for a number of patients surgery is urgent and the procedure cannot be delayed. This situation is challenging as the risks of bleeding due to the antiplatelet therapy and the thrombotic risks of stopping the antiplatelet must be weighed and compared before the surgery \[[@CR4]\]. At the present time, there are no specific guidelines on how to treat a patient on antiplatelet therapy who requires urgent non-cardiac surgery. This lack of information is due to the absence of randomized trials exploring this issue. However, a few studies have tested different types of bridging strategies. Bridging in this context refers to "the temporary administration of an antithrombotic agent preoperatively in order to minimize the time period that a patient remains free from antithrombotic protection between withdrawal of oral antiplatelet therapy and the time of surgery" (Anastasiou et al., p 137 \[[@CR1]\]). The different agents utilized in these bridging strategies include heparin and glycoprotein (GP) IIb/IIIa inhibitors, both of which have drawbacks, particularly in this setting. However, cangrelor, a novel direct-acting, reversible P2Y~12~ receptor inhibitor can be used similarly to adenosine diphosphate (ADP) receptor antagonists. Cangrelor can be administered intravenously, and it has a rapid onset and offset, making it valuable for use in urgent peri-operative situations where there is a high risk of stent thrombosis. In the specific case reported here, cangrelor was used in an innovative method of bridging a high-risk patient with a recent stent placement who required emergent surgery to remove a soft tissue sarcoma in his left chest region.

Case Information {#Sec2}
================

A 46-year-old man was admitted to the hospital with an acute anterior wall myocardial infarction. He was urgently taken to the catheterization lab where he was found to have a totally occluded proximal left anterior descending coronary artery (LAD). The LAD was successfully stented, following which the patient had a 40% mid-right coronary artery lesion and ejection fraction of approximately 40--45% with an apical wall motion abnormality, which was subsequently confirmed on an echocardiogram. He did well post intervention without any further chest pain, dyspnea, or symptoms consistent with myocardial ischemia. He had an unremarkable post-procedural course and was discharged on combined therapy of aspirin 325 mg a day, atorvastatin 80 mg a day, metoprolol 50 mg twice daily, prasugrel 10 mg a day, and ramipril 5 mg.

Two months after this successful cardiac procedure, the patient returned with a new chest mass. He now presented for preoperative clearance for a possible sarcoma of the left chest. The ejection fraction at the patient's first presentation was 40%, and a subsequent repeat echocardiogram showed well-preserved left ventricular systolic function of 55%.

Due to his recent anterior wall myocardial infarction and placement of drug-eluting stent, the patient was currently taking prasugrel and aspirin. Surgeons in the General Surgery department were consulted, and they were not willing to operate on the patient while he was on aspirin and prasugrel given the invasive nature of the procedure and the high risk of bleeding. It was then decided to use cangrelor as a bridging agent for this procedure.

The patient discontinued prasugrel 2 days prior to being admitted to the hospital, but continued on aspirin. He was then started on 4 mcg/kg/min of cangrelor and continued this treatment for the next 3 days. The drug was stopped 1 h prior to entrance into the operating room where he underwent a biopsy and excision of the soft tissue sarcoma. The patient tolerated the procedure well. He was then started on 60 mg of prasugrel 48 h after the procedure and continued on this agent at a dose of 10 mg per day. He experienced no further issues. All of his post-operative checkups and tests were normal, and the patient experienced no complications.

Informed consent was obtained from the individual participant for inclusion in the study.

Discussion {#Sec3}
==========

The patient presented with a soft tissue sarcoma that needed urgent excision. This proved a challenge as the patient was currently on aspirin and prasugrel therapy, and withdrawal of the ADP receptor antagonist (P2Y~12~) would put the patient at high risk of acute stent thrombosis. To avoid this risk, antiplatelet therapy needed to continue for as close to the surgical procedure as possible. There have been several small studies using either heparin or GP IIb/IIIa receptor inhibitors as bridging agents; however, the results gave no clear indication of whether these agents were successful. The direct, fast-acting and reversible nature of cangrelor makes it an appealing option for avoiding thrombotic risks as well as the risk of surgical bleeding.

The pharmacologic profiles of such oral antiplatelets as clopidogrel, prasugrel, and ticagrelor have led researchers to study different agents that could potentially be used in antiplatelet-bridging strategies. Clopidogrel and prasugrel are prodrugs whose active metabolites bind to the P2Y~12~ receptor for the lifespan of the platelet (about 7--10 days), thus requiring drug discontinuation 5--7 days before surgery \[[@CR3]\]. Although P2Y~12~-receptor binding by ticagrelor is reversible, discontinuation 5 days before surgery is still recommended. Such waiting periods are unfavorable to the patient as he/she is without an antithrombotic medication for 5--7 days, which puts that patient at risk for acute stent thrombosis.

Given our patient's recent history, we were concerned that heparin or GP IIb/IIIa receptor inhibitors would cause significant complications. Unfractionated heparin and low molecular weight heparins are potential agents for possible bridging strategies. Heparin can affect platelet reactivity, either positively or negatively, making its effect inconsistent \[[@CR1]\]. Two studies have evaluated the perioperative use of heparins in patients with coronary stents; neither revealed any consistent protective effect of these agents against stent thrombosis. These studies also found an increase in bleeding events \[[@CR1]\]. The lack of evidence supporting the safety of heparins discourages their use for bridging situations. Intravenous GP IIb/IIIa inhibitors have also been researched as potential bridging agents. The two small-molecule GP IIb/IIIa inhibitors with reversible inhibition are eptifibatide and tirofiban \[[@CR1]\], although their offset of effect is several hours. Despite their theoretically applicable pharmacologic profile, evidence from randomized trials is lacking, and the results of small nonrandomized or retrospective studies have been inconsistent \[[@CR1]\]. The lack of consistent success with these bridging agents led us to consider cangrelor.

Cangrelor is an intravenous P2Y12 inhibitor with a very short plasma half-life of about 3--5 min that can reversibly block the platelet P2Y12 receptor. This short half-life and direct administration allows for a rapid offset of action within 1 h of cessation of administration, while the onset of action is immediate \[[@CR1]\]. Cangrelor's ability to work directly on the P2Y12 receptor on platelets---as compared with GP IIb/IIIa inhibitors---potentially makes it a valuable bridging medication. In the BRIDGE study, cangrelor for bridging thienopyridine-treated patients to CABG surgery was tested against a placebo. The results showed that cangrelor maintained an adequate level of platelet inhibition that was similar to the level expected with clopidogrel \[[@CR2]\].

Conclusion {#Sec4}
==========

Cangrelor was successfully used to bridge a patient with a recent stent placement and currently on antiplatelet treatment who required surgery for the removal of a soft tissue sarcoma. It is not uncommon for some patients on antiplatelet therapy to subsequently require urgent non-cardiac surgery. There is currently a lack of clinical trials and no specific guidelines on how to treat a patient on an oral ADP receptor antagonist who requires urgent non-cardiac surgery. Some trials have evaluated the bridging ability of agents such as heparin and GP IIb/IIIa inhibitors, but the results have been inconsistent and unsuccessful. The pharmacologic characteristics of the P2Y12 receptor inhibitor cangrelor, namely, its fast onset and offset of effect, potentially make it an ideal bridging agent. This case report demonstrates the use of this novel, now currently available, short-acting antiplatelet agent that can be used for bridging patients undergoing non-cardiac surgery who had a recent myocardial infarction and stent placement.
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